Medical Treatment of JJ Stent-related Symptoms

Athanasios Dellis1, George Daglas1 and Athanasios Papatsoris1,2*

1Department of Urology, University of Athens, Sismanoglio General Hospital, Athens, Greece
2Department of Urology, Royal London Hospital, Bartshealth NHS Trust, London, UK

Although ureteric JJ stents have been widely used in Urology for many decades and their placement is considered a routine procedure, they are associated with significant morbidity and a negative impact on patient’s quality of life [1]. Furthermore there is no consensus regarding stent placement after ureteroscopic stone removal or whether it is needed before Extracorporeal Shock Wave Lithotripsy (ESWL) [2]. Joshi et al. recognized patient morbidity associated with ureteral JJ stents as a significant health problem and developed a validated questionnaire (USSQ: Ureteric Symptom Score Questionnaire) [3]. USSQ has been used to determine whether novel stent designs, shapes, material or drug coatings confer any improvement in JJ stent related symptoms and/or if medications decrease JJ stent related morbidity. However, despite ongoing research, the ideal ureteric stent has yet to be discovered.

Several pharmaceutical studies and meta-analyses demonstrate a consistent beneficial effect of α-blockers in patients with indwelling ureteral JJ stents [3-13]. The administration of a selective α-blocker, such as alfuzosin or tamsulosin, improves stent related urinary symptoms, especially pain. In addition, sexual function and general health may be better preserved. Deliveliotis et al. demonstrated that α-blockers had a positive impact on JJ stent related symptoms [4]. In their randomized prospective study they compared alfuzosin versus placebo in affecting symptoms and quality of life in patients with indwelling ureteral JJ stents. The authors administered the USSQ four weeks after stent insertion and concluded that alfuzosin improved JJ stent related urinary symptoms and pain, while sexual function and general health were better preserved. In a prospective, randomized, placebo controlled study of 55 patients with indwelling ureteral stents after ureteroscopy Beddingfield et al. reported that alfuzosin markedly decreased the pain associated with ureteral stents but had little effect on urinary symptoms in general [6]. They administered the USSQ preoperatively and 3 days after the procedure, which may have been too early. Damiano et al. performed a prospective randomized study comparing the efficacy of tamsulosin versus placebo for JJ stent related symptoms in 75 patients. The authors concluded that tamsulosin had a positive effect on stent related urinary symptoms and quality of life [10]. Wang et al. performed a prospective randomized trial comparing the effect of tamsulosin vs. placebo on stent related symptoms in 154 patients using the USSQ and the International Prostate Symptom Score (IPSS) [7]. They reported significant differences in the main score index of urinary symptoms, body pain and general health in favor of tamsulosin. Navanimitkul and Lojanapiwat assessed the efficacy of tamsulosin in improving stent-related symptoms and quality of life in patients with indwelling JJ ureteral stents after ureteroscopy, percutaneous nephrolithotomy or balloon dilatation [11]. They used the IPSS and SF-36 questionnaires at 2 and 4 weeks postoperatively. The IPSS and SF-36 scores were significantly better in tamsulosin vs. placebo in affecting symptoms and quality of life. Although the above-mentioned studies were not uniformly designed and in many cases underpowered the positive effect of α-blockers was far from any doubt, while the use of anticholinergics or analgesics needs further evaluation in prospective studies. Most studies did not reported all aspects of USSQ and did not complete it regularly like the study by Dellis et al. where USSQ was completed the 1st and 4th week with the JJ stent in situ and 4 weeks after its removal [9].

The pathophysiology of stent related pain may be related to irritation of the trigone, smooth muscle spasm and/or inflammation in the ureter and bladder. The bigger effect of α-blockers on pain more than on urinary symptoms suggests that smooth muscle spasm in the ureter and bladder has a significant role. Further comparative studies with antimuscarinics, steroids and calcium channel blockers are needed as well as the use of validated questionnaires [14,15].

References


*Corresponding author: Athanasios Papatsoris, Department of Urology, Royal London Hospital, Bartshealth NHS Trust, London, UK, Tel: +306947695995; Fax: +302108044703; E-mail: agpapatsoris@yahoo.gr

Received February 26, 2014; Accepted March 02, 2014; Published March 04, 2014


Copyright: © 2014 Dellis A, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Submit your next manuscript and get advantages of OMICS Group submissions

Unique features:
• User friendly/feasible website-translation of your paper to 50 world's leading languages
• Audio Version of published paper
• Digital articles to share and explore

Special features:
• 350 Open Access Journals
• 30000 editorial team
• 21 days rapid review process
• Quality and quick editorial, review and publication processing
• Indexing at PubMed (partial), Scopus, EBSCO, Index Copernicus and Google Scholar etc
• Sharing Option: Social Networking Enabled
• Authors, Reviewers and Editors rewarded with online Scientific Credits
• Better discount for your subsequent articles

Submit your manuscript at: http://www.omicsonline.org/submission/